Experience with the Use of an Aldosterone Antagonist in Selected Hypertensive Patients

Hollander, W. , and Wilkins, R.W. : The Pharmacology and Clinical Use of Rauw-olfia, Hydralazine, Thiazides, and Aldosterone Antagonists in Arterial Hypertension . Progr. Cardiov. Dis. 8: 291-318, 1966.

Hollander, W. , Chobanian, A.V. , and Williams, R.S. : Potential of the Aldosterone Antagonists in Hypertension in Bartter, F. C. editor. The Clinical Use of Aldosterone Antagonists. Springfield III. Charles C. Thomas Publisher, pp 169-177, 1960.

Hollander, W. , Chobanian, A.V. , and Wilkins, R.W. : The Antihypertensive Actions of Mercurial Thiazide and Spironolactone Diuretics in Buckborn, E. , and Bock, K. D. (editors): Diuresis and Diuretics, an International Symposium, Berlin, Springer-Verlag, 1959 pp 297-312.

Hollander, W. , Chobanian, A.V. , and Wilkins, R.W. : The Role of Diuretics in the Management of Hypertension. Ann. New York Acad Sci 88: 975-989, 1960.

Winer. B.M. : Effects of an Aldosterone Antagonist and a Benzothiadiazine Individually and in Combination in Benign Hypertension. Cir. 24: 1073, 1961.

Kliman, B. , and Peterson, R.E. : Double Isotope Derivative Assay of Aldosterone in Biological Extracts. J. Biol Chem 235: 1639-1648, 1960.

Crabbe, J. : Decreased Effectiveness of Aldosterone on Active Sodium Transport by the Isolated Toad Bladder in the Presence of other Steroids. Acta Endocrinol. 47: 419-432. 1964.

Liddle, G.W. : Aldosterone Antagonists. A.M.A. Arch Intern. Med. 102: 998-1004, 1958.

Jacobs, R.S. , Jiu. J. , and Hofmann, L.M. : Spironolactone: Reversal of NA Retention in the Bilateral Adrenal Enucleated Rat. Arch. Int. Pharmacodyn. 177(1): 245-251. 1969.

Liddle, G.W. : Specific and Non-specific Inhibition of Mineralocorticoid Activity. Metabolism 10: 1021-1030, 1961 .

Kagawa, C.M. , Sturtevant, F.M. , and Van Arman, C.G. : Pharmacology of a New Steroid that Blocks Salt Activity of Aldosterone and Desoxycorticosterone. J. Pharm & Exp. Therap. 126: 123-130, 1959.

Kagawa, C.M. Bouska, D.J. , Anderson, M.L. , Krol, W.F. : Pharmacological Properties of a Mineralocorticoid Antagonist (SC-14266). Arch . Internatl. Pharmaco-dynamics 149: 8-24, 1964.

Kagawa, C.M. : Mineralocorticoid-Blocking Properties of a Progesterone-Like Derivative (SC-11835) . Endocrin 74: 724-730, 1964.

Wolf, R.L. Mendlowitz, M. , Roboz, J. , Styan, G.P.H. , Kornfeld, P. , and Weigh, A. : Treatment of Hypertension with Spironolactone. JAMA 198: 1143, 1966.

Davis, J.O. , Urquhart, J. , and Higgins, J.T. : The Effects of Alterations of Plasma Sodium and Potassium Concentration on Aldosterone Secretion. J. Clin. Invest. 42: 597-609, 1963.

Herman, E. , and Rado, J. : Fatal Hyperkalemic Paralysis Associated with Spironolactone. Arch Neurol 15: 74-77, 1966.

Hofmann, L.M. , and Ahlberg, J.W. : Urinary and Fecal Excretion of Tritium Labeled Spironolactone. The Pharmacologist 10: 155, 1968.

Hofmann, L.M. , and Ahlberg, J.W. : Urinary and Fecal Elimination of 3H-Spironolactone in the Rat. Fed. Proc. 28: 797, 1969.